Cannabinoid Encyclopedia

Safety guide

Liver enzymes and hepatotoxicity: what to know

A source-linked guide to Liver enzymes and hepatotoxicity, the situations researchers have examined, and the details that can change risk.

Updated July 2026 15 research sources Human and early research

The short answer

Why does Liver enzymes and hepatotoxicity matter?

Liver enzymes and hepatotoxicity is an important cannabinoid safety topic. Studies and reviews examine CBD, CBG, CBN, and CBC. This page brings together 11 human-study sources, 3 research reviews, and 1 lab, animal, or mechanism source. The source set includes human research as well as earlier-stage studies. The compound, dose, route, other medications, and individual health context all matter. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about Liver enzymes and hepatotoxicity.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on Liver enzymes and hepatotoxicity covers CBD, CBG, and CBN; those areas should not be combined into one claim. 1

  2. 2

    The source set includes human research as well as earlier-stage studies. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about Liver enzymes and hepatotoxicity

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Human and early-stage research

CBD

Research involving CBD contributes to the larger Liver enzymes and hepatotoxicity question. Risk can change with dose, route, formulation, other substances, medications, and the person being studied. 2

Human and early-stage research

CBG

Research involving CBG contributes to the larger Liver enzymes and hepatotoxicity question. Risk can change with dose, route, formulation, other substances, medications, and the person being studied. 3

Mostly mechanism-focused

CBN

Research involving CBN contributes to the larger Liver enzymes and hepatotoxicity question. Risk can change with dose, route, formulation, other substances, medications, and the person being studied. 4

Human research included

CBC

Research involving CBC contributes to the larger Liver enzymes and hepatotoxicity question. Risk can change with dose, route, formulation, other substances, medications, and the person being studied. 3

Mostly mechanism-focused

Endocannabinoids

Research involving Endocannabinoids contributes to the larger Liver enzymes and hepatotoxicity question. Risk can change with dose, route, formulation, other substances, medications, and the person being studied. 5

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

11 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

3 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

1 source

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on Liver enzymes and hepatotoxicity is not one kind of study. This source set includes 6 clinical studies in people, 3 cell or laboratory studies, 2 narrative or expert reviews, and 1 animal study. 3

The recorded populations or models include people or patients (9 sources), animal models (2 sources), and pediatric, adolescent, or developmental context (2 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is endocannabinoid enzyme activity or metabolic mechanisms (12 sources), safety, adverse-event, impairment, or formulation-specific concerns (2 sources), and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns (1 source). Closely related outcome names can still describe different measurements. 5

The Liver enzymes and hepatotoxicity source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

systematic review or meta-analysis

Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis.

On this page, this source examines CBD activity involving endocannabinoid enzyme activity or metabolic mechanisms. 1

Study type
systematic review or meta-analysis
Population or model
people or patients
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
evidence still limited

animal study

Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine.

On this page, this source examines CBD activity involving endocannabinoid enzyme activity or metabolic mechanisms. 2

Study type
animal study
Population or model
animal models
Outcome focus
endocannabinoid enzyme activity or metabolic mechanisms
Evidence stage
mechanism-focused research

human research

Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract.

On this page, this source examines CBG and safety, adverse-event, impairment, or formulation-specific concerns and CBC and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns. 3

Population or model
people or patients
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns and safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns
Evidence stage
human research

cell or laboratory study

Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids.

On this page, this source examines CBG and safety, adverse-event, impairment, or formulation-specific concerns and CBN and safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns. 4

Study type
cell or laboratory study
Population or model
people or patients
Outcome focus
safety, adverse-event, impairment, or formulation-specific concerns and safety, tolerability, sedation, adverse-event, impairment, or formulation-specific concerns
Evidence stage
mechanism-focused research

clinical study in people

Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region.

On this page, this source examines Endocannabinoids activity involving TRPV4. 5

Study type
clinical study in people
Population or model
animal models
Outcome focus
tRPV4 channel activity, binding, signaling, or pharmacology
Evidence stage
mechanism-focused research

Safety and limits

What should readers keep in mind?

This page is already focused on Liver enzymes and hepatotoxicity. Risk can change with the cannabinoid, amount, route, frequency, formulation, other substances, medications, age, pregnancy, and underlying health conditions. 3

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What is the main research question about Liver enzymes and hepatotoxicity?

The literature on this page centers on CBD, CBG, CBN, and CBC. The source set includes human research as well as earlier-stage studies. 7

How should I read the sources?

Start with the study design, then check the product, dose, route, population, outcome, and safety information. 8

Does this page give medical advice?

No. It explains published research and links to sources; it does not provide a diagnosis, treatment plan, or personal dosing advice. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited PubMed 36912195 DOI 10.1111/joim.13627
  2. 2
    Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. animal study; mechanism-focused research PubMed 25999668 DOI 10.1155/2015/523418
  3. 3
    Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. human research PubMed 42057192 DOI 10.1186/s42238-026-00432-w
  4. 4
    Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. cell or laboratory study; mechanism-focused research PubMed 39004335 DOI 10.1016/j.tox.2024.153885
  5. 5
    Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region. clinical study in people; mechanism-focused research PubMed 38750093 DOI 10.1038/s41598-024-61791-z
  6. 6
    Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. clinical study in people; mechanism-focused research PubMed 33022751 DOI 10.1002/cpt.2071
  7. 7
    Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. clinical study in people; human research PubMed 40622698 DOI 10.1001/jamainternmed.2025.2366
  8. 8
    Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. clinical study in people; human research PubMed 29768152 DOI 10.1056/nejmoa1714631
  9. 9
    Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model. clinical study in people; mechanism-focused research PubMed 40774642 DOI 10.1016/j.tiv.2025.106126
  10. 10
    Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. human research PubMed 34918948 DOI 10.1089/can.2021.0114
  11. 11
    Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. clinical study in people; evidence still limited PubMed 39630203 DOI 10.1007/s00204-024-03904-1
  12. 12
    Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. narrative or expert review; evidence still limited PubMed 39228144 DOI 10.1111/jgh.16730
See all 15 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Transcriptomic comparison on the mechanism of action of four major constituent cannabinoids in hemp extract. human research / 2 linked research notes PubMed 42057192
  2. Comparison on the mechanism and potency of hepatotoxicity among hemp extract and its four major constituent cannabinoids. cell or laboratory study; mechanism-focused research / 2 linked research notes PubMed 39004335
  3. Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. animal study; mechanism-focused research / 1 linked research note PubMed 25999668
  4. Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 37458709
  5. Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. clinical study in people; evidence still limited / 1 linked research note PubMed 39630203
  6. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. clinical study in people; human research / 1 linked research note PubMed 29768152
  7. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. clinical study in people; human research / 1 linked research note PubMed 40622698
  8. Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase I Clinical Trial. clinical study in people; mechanism-focused research / 1 linked research note PubMed 33022751
  9. Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. human research / 1 linked research note PubMed 34918948
  10. Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40750820
  11. Evaluating cannabidiol-induced liver injury with and without valproate using a three-dimensional human hepatocyte spheroid model. clinical study in people; mechanism-focused research / 1 linked research note PubMed 40774642
  12. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 36912195
  13. Metabolism and liver toxicity of cannabidiol. narrative or expert review; evidence still limited / 1 linked research note PubMed 38904421
  14. Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. narrative or expert review; evidence still limited / 1 linked research note PubMed 39228144
  15. Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region. clinical study in people; mechanism-focused research / 1 linked research note PubMed 38750093